Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis
Launched by MAIMÓNIDES BIOMEDICAL RESEARCH INSTITUTE OF CÓRDOBA · Feb 26, 2016
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
In hemodialysis patients, deviations of serum concentration of calcium, phosphate or parathyroid hormone from the values recommended by KDIGO are associated to a negative outcome. The regulation of calcium, phosphate and parathyroid hormone is complex and each parameter is not independently regulated. In hemodialysis patient's simultaneous modification in these three parameters are the result of abnormal mineral metabolism and the treatment used to correct these abnormalities that usually produce changes in more than one parameter. The specific objective of this work is an accurate and exha...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Incident hemodialysis patients
- • Non acute renal failure
- Exclusion Criteria:
- • Previous treatment with cinacalcet
- • Neoplasia
- • Previous parathyrodectomy
About Maimónides Biomedical Research Institute Of Córdoba
The Maimónides Biomedical Research Institute of Córdoba is a leading research organization dedicated to advancing biomedical science through innovative clinical trials and translational research. Located in Córdoba, Spain, the institute focuses on a multidisciplinary approach to address pressing health challenges, fostering collaboration among researchers, clinicians, and industry partners. Its commitment to excellence in research is complemented by state-of-the-art facilities and a robust ethical framework, ensuring the highest standards of scientific integrity and patient safety. By prioritizing cutting-edge research and the development of novel therapeutic strategies, the Maimónides Biomedical Research Institute aims to contribute significantly to the improvement of global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Córdoba, , Spain
Córdoba, , Spain
Patients applied
Trial Officials
Alejandro Martín Malo, MD
Principal Investigator
Andalusian Public Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials